Agalsidase Beta

ATC A16AB04 · 10 markets · 19 records

Agalsidase Beta 10 markets · 19 records Forms

AU 3 records · 3 strengths

35 mginjectionFABRAZYME agalsidase beta-rch 35mg powder for injection vial also in GB·ES·TW unknown
5.5 mginjectionFABRAZYME agalsidase beta-rch 35mg powder for injection vial unknown

Records without a stated strength · 1 Fabrazyme

US 2 records · 1 strengths

5 mginjectionFabrazyme also in GB·ES·TW

GB 2 records · 2 strengths

35 mginjectionFabrazyme 5mg powder for concentrate for solution for infusion vials also in AU·ES·TW
5 mginjectionFabrazyme 5mg powder for concentrate for solution for infusion vials also in US·ES·TW

CA 2 records · 2 strengths

35 mgpowderFabrazyme
5 mgpowderFabrazyme

SG 2 records · 1 strengths

Records without a stated strength · 1 Fabrazyme ® 5mg (agalsidase beta)

ES 2 records · 2 strengths

35 mginjectionFabrazyme also in AU·GB·TW
5 mginjectionFabrazyme also in US·GB·TW

TW 2 records · 2 strengths

35 mginjectionFABRAZYME Injection 5mg/vial+1法布瑞酶凍晶注射劑35毫克/小瓶 also in AU·GB·ES
5 mginjectionFABRAZYME Injection 5mg/vial+1法布瑞酶凍晶注射劑5毫克/小瓶 also in US·GB·ES

HK 2 records · 1 strengths

Records without a stated strength · 1 FABRAZYME FOR INJ 35MG

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 Fabrazyme

Side-by-side table

Strength / form / release	US	GB	CA	AU	SG	ES	TW	HK	EU
35 mg injection	not recorded	Fabrazyme 5mg powder for concentrate for solution for infusion vials	not recorded	FABRAZYME agalsidase beta-rch 35mg powder for injection vial	not recorded	Fabrazyme	FABRAZYME Injection 5mg/vial 法布瑞酶凍晶注射劑35毫克/小瓶	not recorded	not recorded
5 mg injection	Fabrazyme	Fabrazyme 5mg powder for concentrate for solution for infusion vials	not recorded	not recorded	not recorded	Fabrazyme	FABRAZYME Injection 5mg/vial 法布瑞酶凍晶注射劑5毫克/小瓶	not recorded	not recorded
5.5 mg injection	not recorded	not recorded	not recorded	FABRAZYME agalsidase beta-rch 35mg powder for injection vial	not recorded	not recorded	not recorded	not recorded	not recorded
35 mg powder	not recorded	not recorded	Fabrazyme	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded
5 mg powder	not recorded	not recorded	Fabrazyme	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded
not disclosed unknown	not recorded	not recorded	not recorded	Fabrazyme	not recorded	not recorded	not recorded	FABRAZYME FOR INJ 35MG	Fabrazyme
not disclosed injection	not recorded	not recorded	not recorded	not recorded	Fabrazyme ® 5mg (agalsidase beta)	not recorded	not recorded	not recorded	not recorded

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

3 more strength/form rows are recorded only in CA · SG and are not shown in this table. Hay 3 filas de concentración/forma registradas solo en CA · SG que no se muestran en esta tabla. 另有 3 个规格/剂型仅在 CA · SG 有记录（未在本表显示）。另有 3 個規格/劑型僅在 CA · SG 有記錄（未在本表顯示）。

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.

Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.